DV
Dividend Vision

NVCT — Nuvectis Pharma Inc

Nuvectis Pharma Inc (NVCT)

Total return is 483.4% over the past 4.5 years, 399.5 points ahead of SPY at 83.9%. Its deepest 1-year drawdown was 36.8%.

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for oncology, with its lead candidate NXP900, a small molecule inhibitor of c-Src and YES1 kinases, currently in Phase 1b trials for solid tumors. The company does not currently distribute dividends. Nuvectis appeals to investors with high risk tolerance seeking exposure to early-stage oncology drug development.

NVCT key facts

Asset type
Stock
Asset class
Equity
Inception date
02/04/2022
Last close
$18.96
Market cap
$568,405,376
Average volume
106700.0
Beta
-0.247
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.31